{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["31(9)"],"submitter":["Rodriguez-Moreno JF"],"pubmed_abstract":["<h4>Purpose</h4>Neoadjuvant treatment of bladder cancer is evolving, with immunotherapy demonstrating promising activity. PARP inhibition combined with immune activation has been proposed as a synergistic strategy. We conducted a comprehensive molecular characterization of tumors treated with this combination in the neoadjuvant setting to provide crucial results for rational development.<h4>Patients and methods</h4>A phase II clinical trial was designed to evaluate the combination of anti-PDL1 inhibitor durvalumab and PARP inhibitor olaparib, focusing on biomarker dynamics in both pre- and post-treatment settings. A total of 29 patients were enrolled. Genomic and transcriptomic profiling, as well as analyses of immune cell populations, was conducted at baseline and at the time of cystectom"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pagination":["1644-1656"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12010967"],"repository":["biostudies-literature"],"pubmed_title":["Treatment Efficacy and Molecular Dynamics of Neoadjuvant Durvalumab and Olaparib in Resectable Urothelial Bladder Cancer: The NEODURVARIB Trial."],"pmcid":["PMC12010967"],"pubmed_authors":["Vazquez S","Beltran L","Virizuela JA","Grana-Castro O","Rodriguez-Antona C","de Velasco G","Berraondo P","Gajate P","Madurga R","Rodriguez-Moreno JF","Collado R","Garcia-Donas J","Font A","Alvarez-Fernandez C","Sevillano-Fernandez E","Ruiz-Llorente S","Fernandez R","Lainez N"],"additional_accession":[]},"is_claimable":false,"name":"Treatment Efficacy and Molecular Dynamics of Neoadjuvant Durvalumab and Olaparib in Resectable Urothelial Bladder Cancer: The NEODURVARIB Trial.","description":"<h4>Purpose</h4>Neoadjuvant treatment of bladder cancer is evolving, with immunotherapy demonstrating promising activity. PARP inhibition combined with immune activation has been proposed as a synergistic strategy. We conducted a comprehensive molecular characterization of tumors treated with this combination in the neoadjuvant setting to provide crucial results for rational development.<h4>Patients and methods</h4>A phase II clinical trial was designed to evaluate the combination of anti-PDL1 inhibitor durvalumab and PARP inhibitor olaparib, focusing on biomarker dynamics in both pre- and post-treatment settings. A total of 29 patients were enrolled. Genomic and transcriptomic profiling, as well as analyses of immune cell populations, was conducted at baseline and at the time of cystectom","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 May","modification":"2026-06-01T14:52:02.476Z","creation":"2025-07-06T03:05:34.909Z"},"accession":"S-EPMC12010967","cross_references":{"pubmed":["40298406"],"doi":["10.1158/1078-0432.CCR-24-2890"]}}